Trial Profile
Pilot pharmacoeconomic evaluation of fondaparinux treatment of pulmonary embolism (PE) compared to treatment with unfractionated heparin
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Fondaparinux sodium (Primary) ; Heparin
- Indications Pulmonary embolism
- Focus Therapeutic Use
- 22 Jan 2008 Status changed from initiated to withdrawn prior to recruitment according to ClinicalTrials.gov.
- 15 May 2007 New trial record.